The recent development of nanotechnology has facilitated a dramatic reduction in the size of materials. Nanomaterials are nanometer-sized materials with speciˆc physicochemical properties that are diŠerent from those of the bulk material of the same composition. Such properties make them very attractive for cosmetic and medical applications. However, nanoparticles can act on living cells or bodies at the nano-level resulting in biologically undesirable as well as desirable eŠects. Thus, reduction in particle size from the micro-to nano-scale not only provides beneˆts to diverse scientiˆcˆelds but also poses potential risks to the environment and to human health. Although signiˆcant resources are aimed at exploiting the desirable properties of nanoparticles for applications in medicine or cosmetics there are only limited attempts to evaluate potentially undesirable eŠects in vivo. Thus, there is a pressing need for a careful consideration of the beneˆts and side eŠects to the use of nanoparticles in medicine and cosmetics. In recent years, the majority of toxic biological response induced by nanomaterials (Nanotoxicity) has focused on cell culture systems. However, data from these studies will require veriˆcation from in vivo experiments using animals. An understanding of Toxicokinetics (the relationship between the physical properties of the nanomaterials and their in vivo behavior) would provide a basis for evaluating undesirable eŠects. Moreover, toxicoproteomics may identify predictive bio-markers for examining nanotoxicity. In this review article, we describe the assumptions and challenges in theˆeld of nanotoxicity and describe advances for studying nanotoxicity of nanosilicas using toxicokinetics/toxicoproteomics both in vivo and in vitro.
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Key words-nanomaterial; nanosilica; toxicokinetics; toxicoproteomics Cells were treated with 70 nm-or 1000 nm-nanosilicas (designated SP70 and SP1000 respectively) at the concentration indicated or PBS for 24 h. The rate of proliferation was determined using the 3 
